Who are SODAS MPH's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Low Dose Quillivant XR, ADHD medications, ADHD Medication, NT0102.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/sodas-mph.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

SODAS MPH — Competitive Intelligence Brief

SODAS MPH (SODAS MPH) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Psychostimulant; extended-release methylphenidate. Area: Psychiatry / Neurology.

marketed Psychostimulant; extended-release methylphenidate Dopamine transporter (DAT) and norepinephrine transporter (NET) Psychiatry / Neurology Small molecule Live · refreshed every 30 min

Target snapshot

SODAS MPH (SODAS MPH) — Massachusetts General Hospital. SODAS MPH is a sustained-release formulation of methylphenidate designed to provide extended therapeutic coverage for attention-deficit/hyperactivity disorder (ADHD) symptoms throughout the day.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
SODAS MPH TARGET	SODAS MPH	Massachusetts General Hospital	marketed	Psychostimulant; extended-release methylphenidate	Dopamine transporter (DAT) and norepinephrine transporter (NET)
Low Dose Quillivant XR	Low Dose Quillivant XR	Seattle Children's Hospital	marketed	Central nervous system stimulant; amphetamine-class psychostimulant	Dopamine transporter (DAT); norepinephrine transporter (NET)
ADHD medications	ADHD medications	Göteborg University	marketed	Psychostimulant and non-stimulant ADHD agents	Dopamine transporter (DAT), norepinephrine transporter (NET), and related monoamine systems
ADHD Medication	ADHD Medication	Massachusetts General Hospital	marketed	Psychostimulant or non-stimulant ADHD agent
NT0102	NT0102	Neos Therapeutics, Inc	phase 3	Psychostimulant (methylphenidate prodrug)	Dopamine transporter (DAT) and norepinephrine transporter (NET)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Psychostimulant; extended-release methylphenidate class)

Massachusetts General Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). SODAS MPH — Competitive Intelligence Brief. https://druglandscape.com/ci/sodas-mph. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab